CN1421227A - Medicine for preventing and treating radiative damage - Google Patents
Medicine for preventing and treating radiative damage Download PDFInfo
- Publication number
- CN1421227A CN1421227A CN 02134696 CN02134696A CN1421227A CN 1421227 A CN1421227 A CN 1421227A CN 02134696 CN02134696 CN 02134696 CN 02134696 A CN02134696 A CN 02134696A CN 1421227 A CN1421227 A CN 1421227A
- Authority
- CN
- China
- Prior art keywords
- radiation
- group
- medicine
- radix
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to one kind of medicine for preparing and treating radiative damage. It is prepared with figwort, rehmannia root, ophiopogon root, isatis root, oldenlandia, astragalus root, privet fruit, glossy ganoderma and green tea in certain proportion. It can reduce the death rate of mouse irradiated with the lethal dose, improve the survival quality and raise the immune of mouse with tumor, and has the same anti-tumor effect as radiative ray.
Description
[technical field]
The present invention relates to a kind of being used for the treatment of and the medicine that prevents radiation injury.
[background technology]
Radiation claims lonizing radiation again, and radiation therapy claims radiotherapy again.Radiotherapy is one of main means of treatment of cancer, and many cancer patients can obtain curing with radiotherapy, but the staff who accepts the patient of radiation cure or contact radiation for a long time also can be subjected to the infringement or the damage of radiation, toxic and side effects occurs.People are seeking radioprotectant for a long time, are not used for the treatment of and prevent toxic and side effects due to the radiation but find out an ideal medicine so far yet.
Theory of Chinese medical science thinks that lonizing radiation belong to the heresy of pyretic toxicity, and tumour patient easily causes body body fluid impaired after accepting radiotherapy, and pyretic toxicity is crossed Sheng.Disharmony between QI and blood, taste imbalance and caused by liver and kidney deficiency appear in severe patient.Xerostomia, pharyngalgia, mucous membrane of oropharynx and skin ulceration can appear, symptoms such as tired power, spontaneous perspiration.Therefore, to the toxicity due to the radiation moisturize to promote the production of body fluid, heat-clearing and toxic substances removing, help that cold fills blood, medicine among the nourishing the liver and kidney.
[summary of the invention]
The component of composition of the present invention and each composition is:
Radix Scrophulariae 8-14, Radix Rehmanniae 8-14, Radix Ophiopogonis 8-14, Radix Isatidis 6-10, Herba Hedyotidis Diffusae 5-9, Radix Astragali 7-11, Fructus Ligustri Lucidi 7-11, Ganoderma 5-7, green tea 2-4.
The invention provides a kind of Chinese medicine preparation, be used for the treatment of radiation according to due to toxicity;
The present invention shows by mouse experiment, can effectively reduce mortality of mice behind the lethal dose irradiation with radiation, improves life quality;
The present invention experiment showed, with tumor-bearing mice can not offset the killing effect of radiation to tumor cell, on the contrary, with radiation the synergistic antitumor effect is arranged;
The present invention experiment showed, the immunologic function that can improve tumor-bearing mice and plays antitumor action with tumor-bearing mice;
The present invention presses body surface area and calculates, 10 times of personnel selection consumptions; Press kilogram weight and calculate 100 times of dose singles of personnel selection consumption to observing 7 days behind the mouse stomach, mice has no poisoning manifestations.It is inferior on every Saturdays that the present invention gavages rat with two dosage of height, linked for 12 weeks, and bone marrow and hepatic and renal function are not had any toxicity damage.
[specific embodiment]
Be the present invention's (trade name is radiation recovery oral liquid or capsule, tablet, pill, Emulsion, dissolved granule) testing data relevant below with function.
One: the making of radiation health preparation
Choose superior Radix Scrophulariae 11 gram, the Radix Rehmanniae 11 grams, Radix Ophiopogonis 11 gram, Radix Isatidis 8 grams, Herba Hedyotidis Diffusae 7 grams, Radix Astragali 9 grams, Fructus Ligustri Lucidi 9 grams, Ganoderma 6 grams, green tea 3 grams, soaked 1-2 hour, execute water-bath and decoct, water-bath is concentrated into the 2.5g/ml crude drug, uses for zoopery.
Two: the radiation health is to the protective effect of irradiation with radiation animal
Method: get 100 individual weight 18-22 gram Kunming mouse, be divided into 5 groups, 20 every group.Do not make irradiation with radiation, gavage normal saline for the 1st group.The 2-5 group is accepted single 7.5Gy's (lethal dose) respectively
60After Co gamma-rays whole body shines.The 2nd group gavages normal saline subsequently, and the 3rd, 4,5 group gavages basic, normal, high radiation recovery oral liquid respectively, every day 1 time, and continuous 30 days, observe and write down ordinary circumstance and the dead animal number of animal, calculate the protection index by following formula:
The result:
Table 1 radiation health is to the protective effect of irradiation with radiation animal
Dosage is observed 30 days survival rate The average survival time natural law group K P value
G/kg laboratory animal number have live animal count survival rate (%) (the matched group 30ml (NS) 20 20 100 30 ± 0 of X ± SD)--singly put group 30ml (NS) 20 00 12.5 ± 8.1--1 group of radiation health
*37.18 2 groups of 20 9 45 21.5 ± 8.9 1.73＜0.01 radiation health
*52.5 3 groups of 20 10 50 20.9 ± 9.6 1.68＜0.01 radiation health
*75.0 20 14 70 24.8 ± 8.3 1.99＜0.01* medicament protection group: add after radiation shines and use the radiation health
Three: the collaborative anti-tumor effect of radiation health and radiation
Method: get 7-9 days rat liver cancer ascitic type ascites of growth under aseptic condition, (cell content is about 10 * 10 to become cell suspension with normal saline by 1: 1 dilution proportion
6Individual/ml) at the approaching right armpit subcutaneous vaccination 0.2ml of every Mus.Be divided into 4 groups after the inoculation at random.Every group 20, the 1st group of negative matched group do not made irradiation with radiation, gavages NS every day, totally 10 days; Do not make irradiation with radiation for the 2nd group, gavage the radiation health every day 1 time, totally 10 times; The 3rd group of usefulness
60CO gamma-rays total irradiation 1.5Gy, per two days 1 time, totally 5 times, gavage NS1 every day, totally 10 times; The 4th group of usefulness
60Co γ line total irradiation 1.5Gy, per two days 1 time, totally 5 times.Add every day with the radiation health and gavage totally 10 times 1 time.Put to death animal on the 11st day, and stripped out the tumor piece and weigh, calculate every group of average tumor body weight, calculate tumour inhibiting rate (IR) by following formula
The result:
The collaborative anti-tumor effect of table 2 radiation health and radiation
The heavy P value of the average tumor of drug dose number of animals body weight (g) tumour inhibiting rate group
(g/kg) the beginning result begins result (%) 1 30ml NS 20 18 21.5 28.0 2.14--2 75 20 20 21.4 28.3 1.07 50.0＜0.01 3 30ml NS
*20 20 21.4 22.3 0.74 65.4＜0.01 4 75
*20 20 21.5 23.4 0.392 81.7＜0.01* accepts
60Co radiation gamma 1.5Gy * 5 times
The antitumaous effect of four radiation health and centralizing function
Method: get 7-9 days rat liver cancer ascitic type ascites of growth under aseptic condition, (cell content is about 10 * 10 to become cell suspension with normal saline by 1: 1 dilution proportion
6Individual/ml) at the approaching right armpit subcutaneous vaccination 0.2ml of every Mus.Be divided into negative control group after the inoculation at random, basic, normal, high three the dosage groups of radiation health.Gastric infusion after 24 hours, every day 1 time, continuous 10 days.Drug withdrawal 24 hours is got blood from the eye chamber, surveys the T lymhocyte transformation rate, puts to death animal subsequently, strips out spleen, thymus and tumor piece, calculates tumour inhibiting rate (IR) by following formula
The result:
Table 3 radiation health is to the inhibitory action of rat liver cancer
The average seriously ill sick rate group P value that presses down of dosage number of animals body weight change
(g/kg) (g) before and after ((%) NS control group 30ml 13 13+7.9 1.37 ± 0.49 of X ± SD)--2 group of 52.5 13 13+7.6 0.65 ± 0.23 52.6＜0.01 radiation health 3 group 75.0 13 13+8.3 0.60 ± 0.20 56.2＜0.01 of 1 group of 37.8 13 13+6.7 0.67 ± 0.29 51.1＜0.01 radiation health of radiation health
Table 4 radiation health is to the influence of tumor-bearing mice body weight, spleen weight, thymus weight, spleen index and thymus index
The heavy thymus of body weight (g) the spleen other P value P value spleen index P value thymus index P value of recombinating
Front and back (mg) (mg)
NS 22.4 ± 0.8 30.3 ± 3.9 148.5 ± 45.3-56.9 ± 14.8-4.9-1.9-radiation health 1 group 22.6 ± 0.9 29.4 ± 3.1 141.2 ± 23.4＞0.05 80.8 ± 12.1＜0.001 4.9＞0.05 2.7＜0.001 radiation health 2 group 22.9 ± 0.9 30.6 ± 2.4 17.0 ± 51.1＞0.05 82.1 ± 21.1＜0.001 5.6＞0.05 2.7＜0.001 radiation health 3 group 22.5 ± 1.0 30.7 ± 1.9 18.3 ± 72.1＞0.05 87.0 ± 15.0＜0.001 6.0＞0.05 2.8＜0.001
Annotate: numeral is the meansigma methods of every group of 13 animals in the table
Table 5 radiation health is to the influence of tumor-bearing mice lymhocyte transformation rate
Dosage lymphocyte transformation (%)
Group P value
(g/kg) (n＝13， X±SD)
3 group 75.0 50.86 ± 22.19＜0.01 of 2 group 52.5 48.07 ± 25.57＜0.01 radiation health of 1 group 37.8 47.16 ± 16.87＜0.01 radiation health of NS 30ml 24.22 ± 16.89-radiation health
Claims (1)
1, a kind of medicine that is used for the treatment of with the prevention radiation injury is characterized in that it is the medicament of being made by the following weight proportion raw material: Radix Scrophulariae 8-14, Radix Rehmanniae 8-14, Radix Ophiopogonis 8-14, Radix Isatidis 6-10, Herba Hedyotidis Diffusae 5-9, Radix Astragali 7-11, Fructus Ligustri Lucidi 7-11, Ganoderma 5-7, green tea 2-4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021346968A CN1302798C (en) | 2002-09-07 | 2002-09-07 | Medicine for preventing and treating radiative damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021346968A CN1302798C (en) | 2002-09-07 | 2002-09-07 | Medicine for preventing and treating radiative damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1421227A true CN1421227A (en) | 2003-06-04 |
| CN1302798C CN1302798C (en) | 2007-03-07 |
Family
ID=4747847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021346968A Expired - Fee Related CN1302798C (en) | 2002-09-07 | 2002-09-07 | Medicine for preventing and treating radiative damage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1302798C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250653A (en) * | 2015-09-29 | 2016-01-20 | 河南海丝克生物科技股份有限公司 | Anti-radiation traditional Chinese medicine health care capsule and preparation method thereof |
| CN111249369A (en) * | 2020-02-11 | 2020-06-09 | 碧豫药业有限责任公司 | Traditional Chinese medicine with anti-tumor and radiotherapy and chemotherapy toxic and side effects relieving functions |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102145068B (en) * | 2011-03-25 | 2012-07-18 | 吉林医药学院 | Microwave radiation protection composition and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090191A (en) * | 1993-01-19 | 1994-08-03 | 陈崇尚 | Be used to improve human leukocytes, hematoblastic Chinese patent medicine and preparation technology thereof |
| CN1061540C (en) * | 1996-12-16 | 2001-02-07 | 空军司令部防化研究所 | Anti-radiation health care liquid and preparation method thereof |
-
2002
- 2002-09-07 CN CNB021346968A patent/CN1302798C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250653A (en) * | 2015-09-29 | 2016-01-20 | 河南海丝克生物科技股份有限公司 | Anti-radiation traditional Chinese medicine health care capsule and preparation method thereof |
| CN111249369A (en) * | 2020-02-11 | 2020-06-09 | 碧豫药业有限责任公司 | Traditional Chinese medicine with anti-tumor and radiotherapy and chemotherapy toxic and side effects relieving functions |
| CN111249369B (en) * | 2020-02-11 | 2021-07-23 | 碧豫药业有限责任公司 | Traditional Chinese medicine with anti-tumor and radiotherapy and chemotherapy toxic and side effects relieving functions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1302798C (en) | 2007-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN101091769B (en) | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method | |
| CN1233389C (en) | Chinese materia medica preparation made from gen-seng and astragalus root for strengthening the body resistance and anti cancer as well as producing method | |
| CN1302798C (en) | Medicine for preventing and treating radiative damage | |
| CN100336552C (en) | Medicine for treating lung cancer | |
| CN1957997A (en) | Animal use compound medicament with effects of relieving the muscles and skin, clearing away heat, relieving darrhea, and relieving dysentery, and preparation method | |
| CN1273173C (en) | New use of medicine for preventing and treating radiative damage | |
| CN1225258C (en) | Chinese medicine compound preparation for curing pancreatic cancer | |
| CN108186794A (en) | A kind of Chinese medicine composition for treating malignant tumour and its preparation method and application | |
| CN1857605A (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN100406026C (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN1056752C (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN112220846A (en) | Traditional Chinese medicine composition for treating children's chronic cough and application thereof | |
| CN106619870B (en) | Composition for treating digestive system tumor and preparation method thereof | |
| CN1911277A (en) | Medicine for treating leukopenia | |
| CN1895554A (en) | Chinese herb for inhibiting tumor and its preparation | |
| CN1042495C (en) | Medicine for benefitting Qi, removing cancer and raising leucocyte and its prepn. | |
| CN105213780B (en) | A kind of Chinese medicine composition that treating chronic gastritis and its application | |
| CN113244204B (en) | Application of zingiberenone A in preparation and/or application of zingiberenone A as product for enhancing body immunity | |
| CN103800844B (en) | A kind of pharmaceutical composition for the treatment of acute pancreatitis and preparation method thereof | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN114831312B (en) | Traditional Chinese medicine composition composed of ganoderma lucidum polysaccharide and cicada fungus polysaccharide and application thereof | |
| CN102872374B (en) | Chinese medicinal composition for assisting tumor radiotherapy | |
| CN114515310B (en) | Pharmaceutical composition for preventing and/or treating myelosuppression caused by radiotherapy and chemotherapy | |
| CN101007114B (en) | An adjuvant drug or health food for tumor patients and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070307 Termination date: 20100907 |